Millipore Sigma Vibrant Logo

382148 Histone Deacetylase Inhibitor II - CAS 174664-65-4 - Calbiochem

The Histone Deacetylase Inhibitor II, also referenced under CAS 174664-65-4, controls the biological activity of Histone Deacetylase. This small molecule/inhibitor is primarily used for Cell Structure applications.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: CBHA, m-Carboxycinnamic Acid bis-Hydroxamide

Primary Target: HDAC
View Products on Sigmaaldrich.com
382148
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
174664-65-4C₁₀H₁₀N₂O₄

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
382148-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma.
      Catalogue Number382148
      Brand Family Calbiochem®
      SynonymsCBHA, m-Carboxycinnamic Acid bis-Hydroxamide
      References
      ReferencesCoffey, D.C., et al. 2001. Cancer Res. 61, 3591.
      Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
      Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
      Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
      Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
      Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.
      Product Information
      CAS number174664-65-4
      ATP CompetitiveN
      DeclarationNot available for sale in the United States.
      FormOff-white solid
      Hill FormulaC₁₀H₁₀N₂O₄
      Chemical formulaC₁₀H₁₀N₂O₄
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetHDAC
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      382148-5MG 04055977213157

      Documentation

      Histone Deacetylase Inhibitor II - CAS 174664-65-4 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Histone Deacetylase Inhibitor II - CAS 174664-65-4 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      382148

      Références bibliographiques

      Aperçu de la référence bibliographique
      Coffey, D.C., et al. 2001. Cancer Res. 61, 3591.
      Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
      Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
      Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
      Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
      Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.

      Informations techniques

      Titre
      White Paper - The Message in the Marks: Deciphering Cancer Epigenetics
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-April-2011 RFH
      SynonymsCBHA, m-Carboxycinnamic Acid bis-Hydroxamide
      DescriptionA cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma cells, which can be blocked by Caspase Inhibitor Z-VAD-FMK (Cat. No. 627610).
      FormOff-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number174664-65-4
      Chemical formulaC₁₀H₁₀N₂O₄
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesCoffey, D.C., et al. 2001. Cancer Res. 61, 3591.
      Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
      Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
      Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
      Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
      Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.